跳至主要内容
临床试验/CTRI/2022/03/041187
CTRI/2022/03/041187招募中3 期

Evaluating the role of probiotics in prevention of febrile neutropenia in children receiving intensive chemotherapy: A double blind randomized control trial

Kritika Setlur0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • To be started on chemotherapy with expected >20% febrile neutropenia incidence or classified as highly myelosuppressive:
  • a.ALL HR induction
  • b.AML induction
  • c.Soft tissue sarcomas
  • d.NACT or Augmented chemotherapy for Retinoblastoma
  • e.High risk Neuroblastoma
  • f.Ewing’s Sarcoma
  • g.Osteosarcoma

排除标准

  • 1.Patients having received prior chemotherapy
  • 2.Patients having coexisting GIT pathologies at presentation (e.g. Malabsorption, intestinal obstruction)
  • 3.Patients documented to have taken probiotics in the past 6 months duration

研究者

发起方
Kritika Setlur

相似试验